Published in Cancer Res on June 01, 1999
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol (2001) 2.95
Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol (2010) 2.79
The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol (2004) 1.91
Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer (2013) 1.56
Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm (2008) 1.39
Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A (2000) 1.37
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn (2007) 1.35
Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol (2002) 1.31
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (2008) 1.29
Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones (2003) 1.29
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs (2007) 1.18
Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J (2007) 1.16
TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential. J Invest Dermatol (2014) 1.13
Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Nucl Med Biol (2010) 1.11
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation. Clin Cancer Res (2008) 1.08
Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J Cell Biol (2004) 1.07
Integrins as "functional hubs" in the regulation of pathological angiogenesis. Semin Cancer Biol (2009) 1.05
Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Am J Pathol (2005) 1.05
Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J (2010) 1.03
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3. Theranostics (2016) 1.02
Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. Am J Pathol (2006) 1.02
The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis (2003) 0.99
Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. J Clin Invest (2006) 0.99
Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer (2008) 0.97
Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med Genomics (2008) 0.96
cis Interaction of the cell adhesion molecule CEACAM1 with integrin beta(3). Am J Pathol (2001) 0.95
Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med (2007) 0.92
Insulin-like growth factor (IGF) signaling requires αvβ3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation. J Biol Chem (2012) 0.87
RhoGDIbeta lacking the N-terminal regulatory domain suppresses metastasis by promoting anoikis in v-src-transformed cells. Clin Exp Metastasis (2006) 0.87
Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1. Oncoscience (2014) 0.86
Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas. J Neurooncol (2010) 0.85
Vinculin activators target integrins from within the cell to increase melanoma sensitivity to chemotherapy. Mol Cancer Res (2011) 0.83
Disintegrins from snake venoms and their applications in cancer research and therapy. Curr Protein Pept Sci (2015) 0.83
Protein kinase Cα (PKCα) regulates p53 localization and melanoma cell survival downstream of integrin αv in three-dimensional collagen and in vivo. J Biol Chem (2012) 0.82
Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep (2015) 0.79
Ultrasmall integrin-targeted silica nanoparticles modulate signaling events and cellular processes in a concentration-dependent manner. Small (2014) 0.77
Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21. Invest New Drugs (2010) 0.77
Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope. Am J Pathol (2016) 0.76
Stamping vital cells - a force-based ligand receptor assay. Biophys J (2013) 0.76
Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: Antitumor activity in mouse melanoma models. Oncotarget (2016) 0.76
N-myc downstream-regulated gene 1 inhibits the proliferation and invasion of hepatocellular carcinoma cells via the regulation of integrin β3. Oncol Lett (2017) 0.75
Urokinase-controlled tumor penetrating peptide. J Control Release (2016) 0.75
Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model. Mol Ther (2017) 0.75
Tumor angiogenesis: putting a value on plastic GEMMs. Circ Res (2014) 0.75
Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis. Cancer Microenviron (2016) 0.75
Integrin β3/Akt signaling contributes to platelet-induced hemangioendothelioma growth. Sci Rep (2017) 0.75
Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review. Cancers (Basel) (2017) 0.75
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol (1997) 7.14
Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 6.52
Definition of two angiogenic pathways by distinct alpha v integrins. Science (1995) 6.00
Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell (1999) 4.55
CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol (1998) 4.22
Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U S A (1987) 4.17
Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med (1998) 3.85
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest (1995) 3.69
Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol (1994) 3.42
Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol (1991) 3.00
Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol (2001) 2.99
Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol (2001) 2.95
Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest (1992) 2.92
Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell (1998) 2.89
The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest (1999) 2.88
Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol (1998) 2.87
Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A (1996) 2.67
Integrins and cancer. Curr Opin Cell Biol (1996) 2.44
An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci (1995) 2.38
Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol (1993) 2.38
Protein splicing in the maturation of M. tuberculosis recA protein: a mechanism for tolerating a novel class of intervening sequence. Cell (1992) 2.35
Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest (1991) 2.32
Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A (1994) 2.30
Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery (2001) 2.30
Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem (1993) 2.27
Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. J Biol Chem (1990) 2.27
The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest (1995) 2.23
Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase. J Virol (1998) 2.20
Vitronectin and its receptors. Curr Opin Cell Biol (1993) 2.17
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med (2001) 2.16
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest (1996) 2.10
Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol (1994) 2.08
New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem (2000) 2.07
The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin. J Cell Biol (1990) 2.07
Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. J Biol Chem (1999) 2.04
Evidence of selection for protein introns in the recAs of pathogenic mycobacteria. EMBO J (1994) 2.04
Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest (1999) 2.03
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res (1984) 2.01
Integrins and angiogenesis. Curr Top Dev Biol (2004) 2.00
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res (2000) 2.00
Arg-Gly-Asp recognition by a cell adhesion receptor requires its 130-kDa alpha subunit. J Biol Chem (1987) 1.93
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery (2001) 1.90
Induction of the angiogenic phenotype by Hox D3. J Cell Biol (1997) 1.84
Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol (1995) 1.81
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res (1998) 1.80
Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology (1993) 1.79
Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A (2001) 1.79
Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol (1992) 1.78
Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A (2000) 1.76
Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol (2001) 1.72
Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene (2006) 1.71
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res (1987) 1.68
Transient functional expression of alphaVbeta 3 on vascular cells during wound repair. Am J Pathol (1996) 1.67
RANTES promotes growth and survival of human first-trimester forebrain astrocytes. Nat Cell Biol (2001) 1.63
The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit. J Biol Chem (1988) 1.59
Adhesion events in angiogenesis. Curr Opin Cell Biol (2001) 1.59
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem (2001) 1.58
Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem (1996) 1.55
Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J Thromb Haemost (2003) 1.55
Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest (1997) 1.53
Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor. J Biol Chem (1990) 1.52
Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell (2001) 1.51
RGD-dependent linkage between plant cell wall and plasma membrane: consequences for growth. J Cell Biol (1989) 1.51
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol (1996) 1.50
cDNA sequence of the human integrin beta 5 subunit. J Biol Chem (1990) 1.49
Protein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. J Cell Biol (1996) 1.48
Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res (1989) 1.45
Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res (1999) 1.44
Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol (1986) 1.42
Cell-type specific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1. J Biol Chem (1996) 1.42
Plasmin-sensitive dibasic sequences in the third fibronectin-like domain of L1-cell adhesion molecule (CAM) facilitate homomultimerization and concomitant integrin recruitment. J Cell Biol (2000) 1.41
Role of alpha v integrins during angiogenesis. Cancer J (2000) 1.41
Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol (1999) 1.40
Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem (2000) 1.40
Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci U S A (1984) 1.39
O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science (1984) 1.38
Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A (2000) 1.37
Identification of a novel integrin beta subunit expressed on cultured monocytes (macrophages). Evidence that one alpha subunit can associate with multiple beta subunits. J Biol Chem (1990) 1.36
Slow induction of RecA by DNA damage in Mycobacterium tuberculosis. Microbiology (2001) 1.36
A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem (1984) 1.31
Integrins, angiogenesis and vascular cell survival. Chem Biol (1996) 1.30
Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci (1995) 1.29
Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood (1991) 1.28
Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology (2004) 1.28